Summary
Interruption of a continuous subcutaneous insulin infusion, most often due to technical problems occurring during the night, is a not uncommon event whose metabolic consequences have received relatively little attention until now. We have therefore investigated the changes in blood glucose, plasma non-esterified fatty acids, 3-hydroxybutyrate, glucagon and free insulin in eight C-peptide negative Type 1 diabetic patients whose pumps were deliberately stopped between 23.00 h and 05.00 h. A control test with the pump functioning normally was carried out in each patient and the studies were randomized. Considering the values at 23.00 h as reference, interruption of the insulin infusion resulted in (1) a rapid decrease in plasma free insulin significant after 1 h and reaching a nadir of 6±2 mU/l after 6 h; (2) a rise in blood glucose which was significant at hour 3 and reached 17.4±1.9 mmol/l at hour 6; (3) a moderate increase in plasma non-esterified fatty acids which remained in the range of 700–800 μmol/l; (4) an early and linear rise in plasma 3-hydroxybutyrate, significant after 1 h and averaging 1290±140 μmol/l after 6 h; (5) a late increase (hour 5) in plasma glucagon. The second aim of our study was to provide for the patient a precise scheme of insulin supplements administered via the pump and based on blood glucose monitoring (Dextrostix — Glucometer) and semi-quantitative evaluation of ketonuria (Acetest). Resetting the pump at its basal rate at 05.00h and giving insulin supplements (2–8 U) at 06.45 h (with the usual breakfast dose) and again at 10.00 h have proved efficacious in restoring satisfactory metabolic control by noon the day after starting the experiment. These results form practical recommendations to patients undergoing this type of accident.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Pirart J (1977) Diabète et complications dégénératives. Présentation d'une étude prospective portant sur 4400 cas observés entre 1947 et 1973. Diabète Metab 3: 97–107, 173–182 and 245–256
Pickup JC, Keen H, Parsons JA, Alberti KGMM (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1: 204–207
Pickup JC, Keen H (1979) Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics. Lancet 1: 1255–1258
Tamborlane W, Sherwin RS, Genel M, Felig P (1979) Restoration of normal lipid and amino acid metabolism in diabetic patients treated with a portable insulin-infusion pump. Lancet 1: 1258–1261
Keller U, Schade DS (1981) Current status of portable insulin infusion devices. Diabetologia 21: 425–426
Pickup JC, Viberti GC, Bilous RW, Keen H, Alberti KGMM, Home PD, Binder C (1982) Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion. Diabetologia 22: 175–179
Champion MC, Shepherd GAA, Rodger NW, Dupre J (1980) Continuous subcutaneous infusion of insulin in the management of diabetes mellitus. Diabetes 29: 206–212
Dole VP, Meinertz H (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235: 2595–2599
Luyckx AS (1972) Immunoassays for glucagon. In: Lefèbvre PJ, Unger RH (eds) Glucagon, molecular physiology, clinical and therapeutic implications, Pergamon Press, Oxford, pp 285–298
Nakagawa S, Nakayama H, Sossaki T, Yoshimo K, Yu Y, Shimozaki K, Aoki S, Mashimo K (1973) Simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22: 590–600
Sulon J, Demey-Ponsart E, Bauduin P, Sodoyez JC (1978) Radioimmunoassay of corticosterone, cortisol and cortisone: their application to human cord and maternal plasma. J Steroid Biochem 9: 671–676
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Kemmler W, Gerbitz KD, Hauner H, Piwernetz K, Hepp KD, Renner R (1980) The insulin levels necessary for good metabolic control with intravenous insulin therapy. In: Irsigler K, Kunz KN, Owens DR, Regal H (eds) New approaches to insulin therapy, MTP Press, Lancaster, pp 171–179
Kraegen EW (1980) The necessity and feasibility of normalizing plasma insulin levels in diabetics using insulin delivery systems. In: Irsigler K, Kunz KN, Owens DR, Regal H (eds) New approaches to insulin therapy, MTP Press, Lancaster, pp 249–256
Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, Forsham PH (1975) Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 292: 985–989
McGarry JD, Foster DW (1980) Regulation of hepatic fatty acid oxidation and ketone body production. Ann Rev Biochem 49: 395–420
Keen H, Pickup JC, Viberti GC, Bilous R, Williams G (1981) Aspects of continuous subcutaneous insulin infusion in diabetes. Diabetes Care 4: 54–57
Fishman V, Fishman M (1982) Practical problems with insulin pumps. New Engl J Med 306: 1369
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krzentowski, G., Scheen, A., Castillo, M. et al. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 24, 314–318 (1983). https://doi.org/10.1007/BF00251815
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00251815